![学納金サイト [在学生・保護者専用]](/assets/images/BlkFeatured_item_tuition.jpg)
Faculty of Medicine教員紹介：福原 浩
| 氏名 |
フクハラ ヒロシ FUKUHARA, Hiroshi |
|---|---|
| 職位 | 教授 |
| 学内の役職・委員等 | 教授 |
| 所属教室 | |
| 専攻・専門分野（大学院） |
医学専攻 泌尿器科学分野（新課程） 外科系専攻 泌尿器科学分野（旧課程） |
| 担当科目（学部） | 泌尿器科学 |
| 担当科目（大学院） | 泌尿器科学演習、泌尿器腫瘍学 |
| 専門分野 | 泌尿器腫瘍学、腹腔鏡・ロボット手術、ウイルス療法 |
| 研究テーマ | 1.がん治療用ウイルスを用いたウイルス療法 2.泌尿器癌におけるがんゲノム医療 |
| 略歴 | 1995年 東京大学医学部医学科卒業 2001年 米国ハーバード大学(MGH病院) フェロー 2006年 東京大学医学部泌尿器科 講師 2014年 東京大学大学院医学系研究科泌尿器外科 准教授 2018年 杏林大学医学部泌尿器科 教授 |
| 所有する学位 | 博士（医学） |
| 指導医・専門医・認定医、その他の資格等 | 日本泌尿器科学会：専門医・指導医、泌尿器腹腔鏡技術認定医、日本内視鏡外科学会技術認定医、がん治療認定医、腹腔鏡下小切開手術施設基準医認定医、泌尿器ロボット支援手術プロクター認定医、日本遺伝子細胞治療学会認定医 |
| 論文・著書等を含む主要研究業績 |
1. Iwaki T, Kurano M, Sumitani M, Niimi A, Nomiya A, Kamei J, Taguchi S, Yamada Y, Sato Y, Nakamura M, Yamada D, Minagawa T, Fukuhara H, Kume H, Homma Y, Akiyama Y. Lipidomic analysis coupled with machine learning identifies unique urinary lipid signatures in patients with interstitial cystitis/bladder pain syndrome. World J Urol. 43, 233, 2025. 2. Taguchi S, Kawai T, Ambe Y, Kishitani K, Noda M, Kaneko T, Miyakawa J, Nakamura Y, Hoshina H, Obinata D, Yamaguchi K, Kakutani S, Furuya Y, Sato Y, Adachi Y, Sugimoto K, Sato K, Tabata M, Tanaka T, Nara K, Uemura Y, Kamei J, Akiyama Y, Sato Y, Yamada Y, Niimi A, Yamada D, Takada T, Takahashi S, Yamada Y, Miyazaki H, Enomoto Y, Nishimatsu H, Fujimura T, Fukuhara H, Nakagawa T, Takahashi S, Kume H. Physical, but not laboratory, treatment-related adverse events are associated with favorable outcomes of enfortumab vedotin for advanced urothelial carcinoma: A landmark analysis. Int J Urol. 32, 270-279, 2025. 3. Oshina T, Yamada Y, Fujimura T, Taguchi S, Akiyama Y, Kamei J, Kaneko T, Kawai T, Obinata D, Yamada D, Fukuhara H, Nakagawa T, Takahashi S, Kume H. Oncologic and Functional Outcomes of Salvage Robot-Assisted Radical Prostatectomy: Report of the First 10 Cases. Curr Oncol. 31, 4762-4768, 2024. 4. Sugawara K, Taguchi S, Gonoi W, Hanaoka S, Shiomi S, Kishitani K, Uemura Y, Akamatsu N, Inui S, Tanaka K, Yagi K, Kawai T, Nakagawa T, Fukuhara H, Abe O, Kume H, Gonzalez MC, Prado CM, Seto Y. Integrated impact of multiple body composition parameters on overall survival in gastrointestinal or genitourinary cancers: A descriptive cohort study. JPEN J Parenter Enteral Nutr. 48, 746-755, 2024. 5. Kato T, Matsumoto R, Yokomizo A, Tohi Y, Fukuhara H, Fujii Y, Mori K, Sato T, Inokuchi J, Hashine K, Sakamoto S, Kinoshita H, Inoue K, Tanikawa T, Utsumi T, Goto T, Hara I, Okuno H, Kakehi Y, Sugimoto M. Outcomes of active surveillance for Japanese patients with prostate cancer (PRIAS-JAPAN). BJU Int. 134, 652-658, 2024. 6. Nagase M, Ando H, Beppu Y, Kurihara H, Oki S, Kubo F, Yamamoto K, Nagase T, Kaname S, Akimoto Y, Fukuhara H, Sakai T, Hirose S, Nakamura N. Glomerular Endothelial Cell Receptor ADGRF5 and the Integrity of the Glomerular Filtration Barrier. J Am Soc Nephrol. 35, 1366-1380, 2024. 7. Higashihara E, Harada T, Fukuhara H. Juxtaglomerular apparatus-mediated homeostatic mechanisms: therapeutic implication for chronic kidney disease. Expert Opin Pharmacother. 25, 819-832, 2024. 8. Yamada Y, Fujii Y, Kakutani S, Kimura N, Sugimoto K, Hakozaki Y, Sugihara T, Takeshima Y, Kawai T, Nakamura M, Kamei J, Taguchi S, Akiyama Y, Sato Y, Yamada D, Urabe F, Miyazaki H, Enomoto Y, Fukuhara H, Nakagawa T, Fujimura T, Kume H. Development of risk-score model in patients with negative surgical margin after robot-assisted radical prostatectomy. Sci Rep. 14, 7607, 2024. 9. Takeuchi T, Hattori-Kato M, Okuno Y, Nomiya A, Fukuhara H, Zaitsu M, Azuma T. A Genome-Wide Association Study of Prostate Cancer Susceptibility Using Occupational and Environmental Factors as Confounding Factors. Cureus. 16, e52926, 2024. 10. Noda M, Taguchi S, Shiraishi K, Fujimura T, Naito A, Kawai T, Kamei J, Akiyama Y, Yamada Y, Sato Y, Yamada D, Nakagawa T, Yamashita H, Nakagawa K, Abe O, Fukuhara H, Kume H. Six-year outcomes of robot-assisted radical prostatectomy versus volumetric modulated arc therapy for localized prostate cancer: A propensity score-matched analysis. Strahlenther Onkol. 200, 676-683, 2024. 11. Taguchi S, Sugawara K, Gonoi W, Hanaoka S, Shiomi S, Kishitani K, Uemura Y, Akamatsu N, Inui S, Tanaka K, Yagi K, Kawai T, Nakagawa T, Fukuhara H, Abe O, Seto Y, Gonzalez MC, Prado CM, Kume H. The importance of ethnic-specific cut-offs of low muscle mass for survival prediction in oncology. Clin Nutr. 43, 134-141, 2024. 12. Hattori-Kato M, Okuno Y, Zaitsu M, Fukuhara H, Nomiya A, Mikami K, Takeuchi T. Hypomethylation of a CpG Site in the CpG Island of the Aquaporin 1 Gene May Be Involved in the Formation of Adult-Onset Non-communicating Hydrocele Testis. Cureus. 15, e47651, 2023. 13. Okuno Y, Hori M, Hattori-Kato M, Fukuhara H, Nomiya A, Mikami K, Takeuchi T. Structural Analysis of the Colony-Stimulating Factor 3 Gene of Granulocyte Colony-Stimulating Factor-Producing Urothelial Cancer. Cureus, 15, e43981, 2023. 14. Taguchi S, Kawai T, Ambe Y, Kishitani K, Sugimoto K, Miyakawa J, Nakamura Y, Noda M, Kaneko T, Kamei J, Obinata D, Yamaguchi K, Kakutani S, Furuya Y, Sato Y, Uemura Y, Akiyama Y, Yamada Y, Sato Y, Yamada D, Enomoto Y, Nishimatsu H, Fujimura T, Fukuhara H, Nakagawa T, Takahashi S, Kume H. Enfortumab vedotin versus platinum rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched study. Int J Urol., 30, 1180-1186, 2023. 15. Kitamura J, Tambo M, Nishijima A, Masuda K, Miyakawa J, Nakamura Y, Fujiwara M, Kishida T, Ito H, Fukuhara H. Surgical resection in patient with teratoma with somatic-type malignancy transformed into rhabdomyosarcoma resulted in long-term survival. IJU Case Rep., 6, 302-305, 2023. 16. Taguchi S, Kawai T, Buti S, Bersanelli M, Uemura Y, Kishitani K, Miyakawa J, Sugimoto K, Nakamura Y, Niimi F, Kaneko T, Kamei J, Obinata D, Yamaguchi K, Kakutani S, Kanazawa K, Sugihara Y, Tokunaga M, Akiyama Y, Yamada Y, Sato Y, Yamada D, Enomoto Y, Nishimatsu H, Fujimura T, Fukuhara H, Nakagawa T, Takahashi S, Kume H. Validation of a drug-based score in advanced urothelial carcinoma treated with pembrolizumab. Immunotherapy, 15, 827-837, 2023. 17. Fukuhara H, Sato YT, Hou J, Iwai M, Todo T. Fusion peptide is superior to co-expressing subunits for arming oncolytic herpes virus with interleukin 12. Commun Med (Lond). 3, 40, 2023. 18. Iwaki T, Akiyama Y, Nosato H, Kinjo M, Niimi A, Taguchi S, Yamada Y, Sato Y, Kawai T, Yamada D, Sakanashi H, Kume H, Homma Y, Fukuhara H. Deep Learning Models for Cystoscopic Recognition of Hunner Lesion in Interstitial Cystitis. Eur Urol Open Sci. 49, 44-50, 2023. 19. Kinjo M, Masuda K, Nakamura Y, Miyakawa J, Tambo M, Fukuhara H. Comparison of mirabegron and vibegron in women with treatment-naive overactive bladder: a randomized controlled study. Urology 175, 67-73, 2023. 20. Ochiai K, Mochida Y, Nagase T, Fukuhara H, Ymaguchi Y, Nagase M. Upregulation of piezo2 in the mesangial, renin, and perivascular mesenchymal cells of the kidney of Dahl salt-sensitive hypertensive rats and its reversal by esaxerenone. Hypertens Res. 46, 1234-1246, 2023. 21. Kinjo M, Masuda K, Nakamura Y, Taguchi S, Tambo M, Fukuhara H. Does metabolic syndrome influence the efficacy of mirabegron treatment in female patients with overactive bladder? Int Urogynecol J. 34, 853-859, 2023. 22. Sugimoto K, Taguchi S, Kishitani K, Kawai T, Masuda K, Nakamura Y, Kinjo M, Tambo M, Miyakawa J, Akiyama Y, Yamada Y, Sato Y, Yamada D, Nakagawa T, Fukuhara H, Kume H. Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma. BMC Urol. 22, 177, 2022. 23. Taguchi S, Kawai T, Nakagawa T, Miyakawa J, Kishitani K, Sugimoto K, Nakamura Y, Kamei J, Obinata D, Yamaguchi K, Kaneko T, Yoshida K, Yamamoto S, Kakutani S, Kanazawa K, Sugihara Y, Tokunaga M, Matsumoto A, Uemura Y, Akiyama Y, Yamada Y, Sato Y, Yamada D, Enomoto Y, Nishimatsu H, Ishikawa A, Tanaka Y, Nagase Y, Fujimura T, Fukuhara H, Takahashi S, Kume H. Improved survival in real-world patients with advanced urothelial carcinoma: A multicenter propensity score-matched cohort study comparing a period before the introduction of pembrolizumab (2003-2011) and a more recent period (2016-2020). Int J Urol. 29, 1462-1469, 2022. 24. Kato T, Yokomizo A, Matsumoto R, Tohi Y, Miyakawa J, Mitsuzuka K, Sasaki H, Inokuchi J, Matsumura M, Sakamoto S, Kinoshita H, Fukuhara H, Kamiya N, Kimura R, Nitta M, Okuno H, Akakura K, Kakehi Y, Sugimoto M. Comparison of the medical costs between active surveillance and other treatments for early prostate cancer in Japan using data from the PRIAS-JAPAN study. Int J Urol. 29, 1271-1278, 2022. 25. Tohi Y, Kato T, Miyakawa J, Matsumoto R, Sasaki H, Mitsuzuka K, Inokuchi J, Matsumura M, Yokomizo A, Kinoshita H, Hara I, Kawamura N, Hashimoto K, Inoue M, Teishima J, Kanno H, Fukuhara H, Maruyama S, Sakamoto S, Saito T, Kakehi Y, Sugimoto M. Impact of adherence to criteria on oncological outcomes of radical prostatectomy in patients opting for active surveillance: data from the PRIAS-JAPAN study. Jpn J Clin Oncol. 52, 1056-1061, 2022. 26. Watanabe M, Taguchi S, Machida H, Tambo M, Takeshita Y, Kariyasu T, Fukushima K, Shimizu Y, Okegawa T, Fukuhara H, Yokoyama K. Clinical validity of non-contrast-enhanced VI-RADS: prospective study using 3-T MRI with high-gradient magnetic field. Eur Radiol. 32, 7513-7521, 2022. 27. Shishido T, Okegawa T, Hayashi K, Masuda K, Taguchi S, Nakamura Y, Tambo M, Fukuhara H. Laparoscopic retroperitoneal lymph node dissection versus open retroperitoneal lymph node dissection for testicular cancer: A comparison of clinical and perioperative outcomes. Asian J Urol, 9, 119-124, 2022. 28. Mochida Y, Ochiai K, Nagase T, Nonomura K, Akimoto Y, Fukuhara H, Sakai T, Matsumura G, Yamaguchi Y, Nagase M. Piezo2 expression and its alteration by mechanical forces in mouse mesangial cells and renin-producing cells. Sci Rep. 12, 4197, 2022. 29. Kawai T, Taguchi S, Nakagawa T, Kamei J, Nakamura Y, Obinata D, Yamaguchi K, Kaneko T, Kakutani S, Tokunaga M, Uemura Y, Sato Y, Enomoto Y, Nishimatsu H, Fujimura T, Fukuhara H, Takahashi S, Kume H. Impact of immune-related adverse events on the therapeutic efficacy of pembrolizumab in urothelial carcinoma: a multicenter retrospective study using time-dependent analysis. J Immunother Cancer. 10, e003965, 2022. 30. Nakamura Y, Taguchi S, Kinjo M, Tanbo M, Okegawa T, Fukuhara H. Adrenal metastasis in nivolumab-treated renal cell carcinoma: A unique entity as a sanctuary site. Int. J Urol. 29, 597-599, 2022. 31. Yokomizo A, Yonese J, Egawa S, Fukuhara H, Uemura H, Nishimura K, Nagata M, Saito A, Lee T, Yamaguchi S, Nonomura N. Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan. Int J Clin Oncol. 27, 418-426, 2022. 32. Tohi Y, Kato T, Nakamura M, Matsumoto R, Sasaki H, Mitsuzuka K, Inokuchi J, Hashine K, Yokomizo A, Naito H, Hara I, Kawamura N, Inoue M, Fukuhara H, Maruyama S, Sakamoto S, Saito T, Egawa S, Kakehi Y, Sugimoto M. Deferred radical prostatectomy in patients who initially elected for active surveillance: a multi-institutional, prospective, observational cohort of the PRIAS-JAPAN study. Int J Clin Oncol. 27, 194-201, 2022. 33. Kinjo M, Tanba M, Masuda K, Nakamura Y, Tanbo M, Fukuhara H. Comparison of effectiveness between modified transvaginal mesh surgery and vaginal pessary treatment in patients with symptomatic pelvic organ prolapse. Low Urin Tract Symptoms. 14, 64-71, 2022. 34. Oshina T, Taguchi S, Miyakawa J, Akiyama Y, Sato Y, Kawai T, Fukuhara H, Nakagawa T, Kume H. Clinicopathological features and oncological outcomes of urothelial carcinoma involving the ureterovesical junction. Jpn J Clin Oncol. 52, 65-72, 2022. 35. Tohi Y, Kato T, Yokomizo A, Mitsuzuka K, Tomida R, Inokuchi J, Matsumoto R, Saito T, Sasaki H, Inoue K, Kinoshita H, Fukuhara H, Maruyama S, Sakamoto S, Tanikawa T, Egawa S, Ichikura H, Abe T, Nakamura M, Kakehi Y, Sugimoto M. Impact of health-related quality of life on repeat protocol biopsy compliance on active surveillance for favorable prostate cancer; results from a prospective cohort in the Prostate Cancer Research International: Active Surveillance (PRIAS)-JAPAN study. Urol Oncol. 40, 56.e.9-e15, 2022. 36. Kato T, Hirama H, Mitsuzuka K, Maruyama S, Sasaki H, Saito T, Matsumoto R, Sakamoto S, Sakai Y, Fukuhara H, Naya Y, Tsukino H, Hara I, Ogawa O, Hashine K, Fumimasa F, Yokomizo A, Tohi Y, Kakehi Y, Sugimoto M. Reclassification prediction of first-year protocol biopsy on active surveillance of prostate cancer by p2PSA-related parameters: from PRIAS-JAPAN. Prostate Cancer Prostatic Dis. 25, 666-671, 2022. |
| 所属学会 |
日本ウイルス療法学会（副理事長）、日本遺伝子細胞治療学会（理事）、日本泌尿器内視鏡・ロボティクス学会（理事）、 日本泌尿器科学会（代議員）、日本癌学会（評議員）、日本癌治療学会（代議員）、日本尿路結石症学会（評議員）、泌尿器科分子・細胞研究会（評議員）、日本排尿機能学会（代議員）、 東京医学会、日本老年泌尿器科学会、日本内視鏡外科学会、日本ミニマム創泌尿器内視鏡外科学会、米国泌尿器科学会(AUA)、国際禁制学会(ICS)、日本泌尿器腫瘍学会、日本臨床腎移植学会、泌尿器腫瘍放射線(GUTR)研究会、日本間質性膀胱炎研究会 |
| 公的な委員会等の役員・委員歴 | 日本専門医機構 理事 東京地方裁判所 専門委員 |
| 学外活動 | 多摩泌尿器科医会 会長 |
| 学生のみなさんへ | がん治療用ウイルスを用いたウイルス療法の確立を目指しています。 患者さんに負担の少ない低浸襲性手術（ロボット支援手術、腹腔鏡下手術）を専門としています。 |
| 関連サイト | 杏林大学病院泌尿器科学教室 |